Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.

MLA

Tursi, Antonio, et al. “Use of Tofacitinib as First or Second-Line Therapy Is Associated with Better Outcomes in Patients with Ulcerative Colitis: Data from a Real-World Study.” Expert Opinion on Pharmacotherapy, vol. 24, no. 14, Sept. 2023, pp. 1649–56. EBSCOhost, https://doi.org/10.1080/14656566.2023.2230126.

APA

Tursi, A., Mocci, G., Cingolani, L., Savarino, E., Pica, R., Cocco, A., Zippi, M., Napolitano, D., Schiavoni, E., Pugliese, D., Scaldaferri, F., Costa, F., Marzo, M., Serio, M., Scarcelli, A., Bolognini, L., Bendia, E., Maconi, G., Cannatelli, R., & Piergallini, S. (2023). Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study. Expert Opinion on Pharmacotherapy, 24(14), 1649–1656. https://doi.org/10.1080/14656566.2023.2230126

Chicago

Tursi, Antonio, Giammarco Mocci, Linda Cingolani, Edoardo Savarino, Roberta Pica, Andrea Cocco, Maddalena Zippi, et al. 2023. “Use of Tofacitinib as First or Second-Line Therapy Is Associated with Better Outcomes in Patients with Ulcerative Colitis: Data from a Real-World Study.” Expert Opinion on Pharmacotherapy 24 (14): 1649–56. doi:10.1080/14656566.2023.2230126.